Verity Asset Management’s Regulus Therapeutics RGLS Stock Holding History

Verity Asset Management’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-107	Closed	-$140K	–	109
2015 Q2	$140K	Buy	+107	New	+$173K	0.13%	88
2015 Q1	–	Sell	-101	Closed	-$193K	–	103
2014 Q4	$193K	Sell	101 -146	-59%	-$260K	0.19%	74
2014 Q3	$202K	Sell	247 -21	-8%	-$17.8K	0.23%	60
2014 Q2	$258K	Buy	268 +31	+13%	+$26.6K	0.28%	50
2014 Q1	$244K	Buy	237 +73	+45%	+$80.9K	0.25%	55
2013 Q4	$145K	Buy	+164	New	+$141K	0.16%	53

Other funds holding RGLS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Verity Asset Management's RGLS Position: Q3 2015 in Review

Verity Asset Management sold out of Regulus Therapeutics (RGLS) in Q3 2015, closing a stake of 107 shares — an estimated $140K sold.

Verity Asset Management first reported a position in RGLS in Q4 2013 and held it in 6 quarters. The position peaked at $258K in Q2 2014. 92 funds tracked by Wall St. Rank hold RGLS as of Q3 2015.

Verity Asset Management reported no remaining Regulus Therapeutics position as of Q3 2015 after selling out during the quarter.
Verity Asset Management sold 107 Regulus Therapeutics shares in Q3 2015, an estimated $140K.
Verity Asset Management first reported a position in Regulus Therapeutics in Q4 2013 and held it in 6 quarters.
Verity Asset Management's Regulus Therapeutics position peaked at $258K in Q2 2014.
92 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2015.

Based on Verity Asset Management's 13F filing for Q3 2015, filed 13 Nov 2015.